EMBECTA CORP (EMBC)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for EMBC
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EMBC | President and Chief Executive Officer, Embecta Corp. | 57 | ["experienced healthcare executive", "extensive experience in the medical device industry", "experience with global business, operations and manufacturing", "strategy and innovation", "cybersecurity and information systems", "risk and crisis management", "ESG", "regulatory and compliance matters", "experience with institutional investors"] | ["AdvaMed", "LMG Holdings", "Zimmer Biomet Holdings, Inc."] | 2025 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ZBH | Chairman, President and Chief Executive Officer; Chairman, President & CEO, Embecta Corp. | 57 | ["Extensive experience in the medical device industry", "Experience with connected medical devices", "Insights on global business, operations and manufacturing, strategy and innovation, cybersecurity, risk and crisis management, investor relations and regulatory and compliance matters"] | [] | 2026 |
Biography sourced from the proxy statement filing.
President and Chief Executive Officer, Embecta Corp.
Age: 57
Director Since: 2022
Independent: No
Other Public Directorships: Zimmer Biomet Holdings, Inc.
Mr. Kurdikar is the President and Chief Executive Officer of Embecta. Previously, Mr. Kurdikar was the Worldwide President of Diabetes Care at BD. Prior to that role, Mr. Kurdikar was the President and CEO of Cardiac Science Corporation (CSC), a global leader in the manufacturing and marketing of automated external defibrillators for public access markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Mr. Kurdikar's leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical. Prior to that role, Mr. Kurdikar was the Vice President and General Manager, Men's Health, within Urology and Pelvic Health at Boston Scientific. Mr. Kurdikar was in the same role at American Medical Systems (AMS) and led the Men's Health business through a carve-out and sale to Boston Scientific, where Mr. Kurdikar led the business through its integration into Boston Scientific. Before joining AMS, Mr. Kurdikar served as Vice President, Marketing, at Baxter, where he worked on a global commercial initiative to drive market access, and was previously Vice President, Marketing, for the Infusion Systems business for the U.S. region. In his 11 years with Baxter, Mr. Kurdikar held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company.
Mr. Kurdikar is currently a member of the Board of Directors of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), AdvaMed (Advanced Medical Technology Association) and LMG Holdings (a portfolio company of The Riverside Company).
Education:
Mr. Kurdikar holds a Bachelor in Chemical Engineering from the University of Bombay (India). He earned a Master of Science in Chemical Engineering from Washington State University (Washington), a Ph.D. in Chemical Engineering from Purdue University (Indiana), and a Master of Business Administration from Washington University (Missouri).
Qualifications, Skills and Experience:
Mr. Kurdikar is an experienced healthcare executive who brings to the Board his extensive experience in the medical device industry and with medical device technology, experience with global business, operations and manufacturing, consumer/retail, payer and medical reimbursement, strategy and innovation, cybersecurity and information systems, risk and crisis management, ESG, regulatory and compliance matters, as well as experience with institutional investors.